Key result
Drugs that prolong the QT interval can trigger torsades de pointes, requiring rigorous preclinical testing of IKr blockade and careful risk-benefit assessment during drug development.
Design
Review
Authors
Loading...
Calls for vigilant QT monitoring in practice; leaves open refined IKr thresholds for novel agents.
This review outlines the mechanisms of drug-induced QT prolongation and proposes a framework for evaluating the cardiac safety of new drug candidates during development.
Cavero et al. (2000) conducted a review in Drug-induced QT interval prolongation and torsades de pointes. Drugs that prolong QT interval was evaluated. Drugs that prolong the QT interval can trigger torsades de pointes, requiring rigorous preclinical testing of IKr blockade and careful risk-benefit assessment during drug development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: